Narcolepsy Trial, Recruiting NCT06413420 Sponsor: Axsome Therapeutics, Inc. Condition: Narcolepsy
Back to Narcolepsy

Narcolepsy Trial, Recruiting

NCT06413420
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are pregnant, regardless of your age
  • You have been diagnosed with narcolepsy or obstructive sleep apnea (a sleep disorder where breathing stops and starts during sleep), OR you have taken solriamfetol or other medications used to promote wakefulness or stimulants at any point during your pregnancy
  • You live in a country where solriamfetol is approved and available as a treatment for excessive daytime sleepiness related to narcolepsy or obstructive sleep apnea
  • You are willing and able to sign a written consent form to take part in the study
  • You agree to allow your doctor(s) to share your health information with the study registry

Who may not be able to join:

  • Your pregnancy has already ended (for any reason) before you first make contact with the study coordination team
  • You have already had a previous pregnancy included in the main part of this study's records (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 1-877-283-6220

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Axsome Therapeutics, Inc.
Registry
ClinicalTrials.gov
Start date
31 July 2019
Est. completion
1 September 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Long-term Safety

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov